Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 11

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 11
---
 the market price
of our common stock to decline. A substantial majority of the outstanding shares of our common stock are, and the shares of common stock
sold in this offering upon issuance will be, freely tradable without restriction or further registration under the Securities Act.

We have never declared or paid dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future.

Our business requires significant funding, and
we currently invest available funds and earnings in product development. Therefore, we do not anticipate paying any cash dividends on
our common stock in the foreseeable future. We currently plan to invest all available funds and future earnings in the development and
growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of potential gain for
the foreseeable future.

<div align='center'>S-7

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

Certain matters discussed
in this prospectus supplement, including the documents that we incorporate by reference, may constitute forward-looking statements for
purposes of the Securities Act and the Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause
our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed
or implied by such forward-looking statements. The words “plan,” “predict,” “potential,” “continue,”
“anticipate,” “believe,” “estimate,” “may,” “expect,” “will,”
“could,” “project,” “intend” and similar expressions are generally intended to identify forward-looking
statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety
of factors, including, without limitation, those discussed under the captions “Risk Factors,” and elsewhere in this
report. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary
statements. Such forward-looking statements include, but are not limited to, statements about:

| · | the fact that our products and product candidates are subject to time and                                             
 cost intensive regulation and clinical testing and as a result may never be successfully developed or commercialized; |

| · | a substantial portion of our sales derive from products that are without                                                                   
 patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or     
 an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating